Profilo
Marcus Schindler è Chief Scientific Officer & Executive VP-Research di Novo Nordisk A. Ha ricevuto un dottorato dall'Università di Cambridge.
Ultime notizie su Marcus Schindler
Precedenti posizioni note di Marcus Schindler
| Società | Posizione | Fine |
|---|---|---|
| NOVO NORDISK A/S | Direttore Tecnico/Scientifico/R&S | 07/08/2025 |
| INNATE PHARMA | Direttore/Membro del Consiglio | 28/05/2021 |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Corporate Officer/Principal | 01/12/2017 |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Direttore Tecnico/Scientifico/R&S | 01/01/2012 |
Formazione di Marcus Schindler
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Innate Pharma SA
Innate Pharma SA Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes | Health Technology |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Health Technology |
University of Gottingen
University of Gottingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Health Technology |
















